Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Genesys (CEGE) -- Ignore unavailable to you. Want to Upgrade?

To: Londo who wrote (1193)	5/4/2002 4:18:12 PM
From: Mark Adams	Respond to of 1298

Glad you posted that. The scene evolved while my attention was elsewhere. Message 15394540 CEGE 6.47 share of cash, 60 million in 6 yr debt Net of debt- 4.77 share of cash (ignoring 60 million PV of lease finance) ABGX, 200 mill convertable notes 660 mill cash net cash 460, 87 shares 5.28 net cash of 8.9 million Abgenix shares mkt price of 13.10, CEGE value at market of 3.60/shr CEGE value of ABGX trading at net cash-> 5.28*8.9mill/35.6mill -> 1.32/share 4.77+1.32->6.09 CEGE preferreds- dilution?